[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100153126":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":66,"collaborators":10,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":10,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":10,"overallStatus":85,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","OTHER",[8,11,13],{"label":9,"type":10,"description":10,"interventionNames":10},"the group of Jiangzhuo prescription",null,{"label":12,"type":10,"description":10,"interventionNames":10},"the group of fenofibrate",{"label":14,"type":10,"description":10,"interventionNames":10},"the group of placebo",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Fengmei Lian, PHD","CONTACT","0086-010-88001402","lfm565@sohu.com",[22,38,47,57],{"facility":23,"status":24,"city":25,"state":10,"zip":10,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Beijing Chinese Medicine Hospital","RECRUITING","Beijing","China","CN",{"type":29,"coordinates":30},"Point",[31,32],116.39723,39.9075,{"lat":32,"lon":31},[35],{"name":36,"role":18,"phone":37,"phoneExt":10,"email":10},"Bai Chang, PHD","13611089962",{"facility":39,"status":24,"city":25,"state":10,"zip":10,"country":26,"countryCode":27,"cosmosGeoPoint":40,"geoPoint":42,"contacts":43},"Beijing Ji Shui Tan Hospital",{"type":29,"coordinates":41},[31,32],{"lat":32,"lon":31},[44],{"name":45,"role":18,"phone":46,"phoneExt":10,"email":10},"Xia Wang","13681007636",{"facility":48,"status":24,"city":25,"state":10,"zip":10,"country":26,"countryCode":27,"cosmosGeoPoint":49,"geoPoint":51,"contacts":52},"Beijing Medical University,DONGZHIMEN Hospital",{"type":29,"coordinates":50},[31,32],{"lat":32,"lon":31},[53],{"name":54,"role":18,"phone":55,"phoneExt":10,"email":56},"Hongfang Liu, PHD","0086-010-84013243","lhfdoctor@sohu.com",{"facility":58,"status":24,"city":25,"state":10,"zip":10,"country":26,"countryCode":27,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"Civil Aviation General Hospital",{"type":29,"coordinates":60},[31,32],{"lat":32,"lon":31},[63],{"name":64,"role":18,"phone":65,"phoneExt":10,"email":10},"Yu Zhao, PHD","13522424090",{"type":10,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":5,"oldOrganization":5},"100153126","jiangzhuo-prescription-fenofibrate-and-placebo-in-the-treatment-of-hyperlipidemia-syndrome-of-phlegm-obstructionclinical-study-jzf-100153126",false,"NCT01265160","Jiangzhuo Prescription ，Fenofibrate and Placebo in the Treatment of Hyperlipidemia (Syndrome of Phlegm Obstruction)Clinical Study (JZF)","JZF","Inclusion Criteria:\n\n* 1\\. Consistent with diagnosed hyperlipidemia, TG≥2.26mmol\u002FL and ≤7.0mmol\u002FL. 2. Aged 18-65 years old. 3.BMI ≥ 24kg\u002Fm2, but \\\u003C35 kg\u002Fm2. 4. Waist circumference ≥ 90cm (male) or waist circumference ≥ 80cm (women). 5. Comply with any of the following 3 :bloode pressure elevated levels of:SBP ≥130mmHg or DBP ≥85mmHg; fasting plasma glucose (FPG) increased: FPG ≥ 100mg\u002Fdl (5.6mmol \u002F l ), or previously diagnosed type 2 diabetes or have received appropriate treatment.\n\nExclusion Criteria:\n\n* 1\\. Has been used to control lipidsdrugs, but use the time for those below the 3 month.\n\n  2.Secondary dyslipidemia, such as nephrotic syndrome, hyperthyroidism, etc. 3.Taking thyroid medications and other drugs that affect lipid metabolism, such as high-dose thiazide diuretics, β-receptor blockers, corticosteroids.\n\n  4.Severe diseases of heart, lung, liver, kidney, brain, blood ,etc. 5.With the treatment of insulin, sulfonylureas, rosiglitazone or metformin. 6.3 months prior to the study of myocardial infarction or unstable angina confirmed.\n\n  7.Uncontrolled blood sugar or after controlling FPG\\>7.0mmol\u002FL or 2hPG\\>11.1mmol\u002FL 8.Uncontrolled blood pressure or after contraolling blood pressure\\>140\u002F90mmHg 9.ALT≥80mmol\u002FL 10.Pregnancy, for pregnancy or breast-feeding women 11.Allergis of fibrates or Chinese medicine 12.Mental illness 13.Cancer patients 14.History of gallbladder disease or cholelithiasis 15.With the treatment of Cyclosporine or coumarin anticoagulants 16.The patient with other clinical studies in the past 3 months 17.History of alcoholism and drug dependence","ALL","18 Years","65 Years",{"count":78,"type":79},240,"ESTIMATED","OBSERVATIONAL","Jiangzhuo prescription ,fenofibrate and placebo in the treatment of hyperlipidemia(syndrome of phlegm obstruction), randomized, parallel-controlled, multi-center clinical study",[83,84],"Metabolic Syndromes","Hyperlipidemia","UNKNOWN","2010-12-22",{"date":88,"type":79},"2010-12-23",{"date":90,"type":10},"2010-11",{"date":92,"type":79},"2011-06",{"name":5,"class":6},4]